Hideki Nakayama

8PUBLICATIONS
16CO-AUTHORS
Immunogenetics (incl. genetic immunology)Medical bacteriologyInfant and child healthCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 31, 2022
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).

Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu

|Feb 16, 2021
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

Takashi Taga, Shiro Tanaka, Daisuke Hasegawa

|Sep 29, 2020
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.

Hiroshi Moritake, Shiro Tanaka, Takako Miyamura

|Aug 04, 2017
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.

Hideki Nakayama, Daisuke Tomizawa, Shiro Tanaka

Pageof 2

Frequent Collaborators

3 joint publications

Hiroshi Moritake

3 joint publications

Takako Miyamura

3 joint publications

Daisuke Hasegawa

3 joint publications

Shotaro Iwamoto